No Data
Denali Therapeutics Advances Brain Disease Therapies
We're Hopeful That Denali Therapeutics (NASDAQ:DNLI) Will Use Its Cash Wisely
Denali Therapeutics Insider Sold Shares Worth $1,932,665, According to a Recent SEC Filing
BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $34
Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
B.Riley Financial Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $33
No Data
No Data